That’s interesting. Is it common for the brand to discontinue the original drug once several generic alternatives are available?
Do you know if additional generics can still get approved after the brand is discontinued? Can they still rely on the brand’s initial trial data for bioequivalency even if the company has discontinued the branded/original drug?
News 
Market Data 
Discover 
